Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0103 USD | -8.04% | -2.83% | -53.18% |
Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Financials (USD)
Sales 2021 | 1.08 | Sales 2022 | 1.27 | Capitalization | 1.76M |
---|---|---|---|---|---|
Net income 2021 | -19M | Net income 2022 | -58M | EV / Sales 2021 | 17,166,252 x |
Net cash position 2021 | 6.35 | Net Debt 2022 | 2.68 | EV / Sales 2022 | 1,390,484 x |
P/E ratio 2021 |
-0.76
x | P/E ratio 2022 |
-0.02
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.98% |
Latest transcript on Baudax Bio, Inc.
1 day | -8.04% | ||
1 week | -2.83% | ||
Current month | -20.77% | ||
1 month | -39.41% | ||
3 months | -59.13% | ||
6 months | -93.82% | ||
Current year | -53.18% |
Managers | Title | Age | Since |
---|---|---|---|
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Natalie McAndrew
DFI | Director of Finance/CFO | 50 | 23-10-08 |
Diane Myers
PRN | Corporate Officer/Principal | 60 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 19-11-20 | |
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Wayne Weisman
CHM | Chairman | 68 | 19-11-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.0103 | -8.04% | 14 336 |
24-04-25 | 0.0112 | +6.67% | 7,116 |
24-04-24 | 0.0105 | -0.94% | 6,065 |
24-04-23 | 0.0106 | -5.36% | 5,960 |
24-04-22 | 0.0112 | +5.66% | 24,717 |
Delayed Quote OTC Markets, April 26, 2024 at 11:59 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-53.18% | 588K | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- BXRXQ Stock